back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2026-03-04 20:39 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Brooks III, John Lawrence
4 - Director of Issuer
Holder: Brooks Family Office LLC (Control or Direction)
|
Convertible Notes (US$)
16 - Acquisition or disposition under a prospectus exemption
|
+$25,000 vol |
$25,000 | |
| Filed 2026-03-04 20:24 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Brooks III, John Lawrence
4 - Director of Issuer
Holder: Brooks Family Office LLC (Control or Direction)
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$25,000 vol |
||
| Filed 2026-03-04 14:58 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Brooks III, John Lawrence
4 - Director of Issuer
Holder: Brooks Family Office LLC (Control or Direction)
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$25,000 vol |
$25,000 | |
| Filed 2026-03-04 14:58 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Brooks III, John Lawrence
4 - Director of Issuer
Holder: Brooks Family Office LLC (Control or Direction)
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$25,000 vol |
||
| Filed 2026-03-04 14:57 Tx date 2024-12-11 |
$SHRX
Sharp Therapeutics Corp. |
Brooks III, John Lawrence
4 - Director of Issuer
Holder: Brooks Family Office LLC (Control or Direction)
|
Convertible Notes
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2026-02-27 15:23 Tx date 2026-02-24 |
$SVA
Sernova Biotherapeutics Inc. |
Brooks III, John Lawrence
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$93,000
+620,000 vol $0.15 each |
1,144,697 | |
| Filed 2026-02-27 15:21 Tx date 2026-02-24 |
$SVA
Sernova Biotherapeutics Inc. |
Brooks III, John Lawrence
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$78,704
+524,697 vol $0.15 each |
524,697 | |
| Filed 2026-02-27 15:20 Tx date 2025-09-22 |
$SVA
Sernova Biotherapeutics Inc. |
Brooks III, John Lawrence
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2026-01-22 10:59 Tx date 2025-05-21 |
$SHRX
Sharp Therapeutics Corp. |
Brooks III, John Lawrence
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+40,000 vol |
40,000 | |
| Filed 2026-01-22 10:58 Tx date 2024-12-11 |
$SHRX
Sharp Therapeutics Corp. |
Brooks III, John Lawrence
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|